


# At A Glance



**A**viragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has four Phase 2 clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir is also being evaluated for the treatment of RV infections in hematopoietic stem cell transplant patients; BTA585, an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, a topical antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit [aviragentherapeutics.com](http://aviragentherapeutics.com)



- > Four clinically active Phase 2 programs
- > Two Phase 2 trials with enrollment complete
  - Vapendavir - Top-line data from the Phase 2b SPIRITUS trial are expected in February.
  - BTA585 - Top-line data from the Phase 2a RSV Challenge trial are expected around the end of January.
- > Strong IP portfolio